Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cheng-Hsin Chu

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
European Journal of Cancer (Oxford, England : 1990)|November 22, 2025
Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort studyTeng-Yu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|February 7, 2025
High-normal and abnormal alanine transaminase levels linked to increased risk of hepatoma following treatment for chronic hepatitis CYen-Chun Chen, Pei-Chien Tsai, Chung-Feng Huang, et al.
Clinical and Molecular Hepatology|February 5, 2025
Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort studyShou-Wu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.
The American Journal of Gastroenterology|March 30, 2020
Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)Chung-Feng Huang, Hsueh-Chou Lai, Chi-Yi Chen, et al.
Hepatology International|August 8, 2021
Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)Ming-Lun Yeh, Chao-Hung Hung, Kuo-Chih Tseng, et al.
American Journal of Cancer Research|August 15, 2022
Risk stratification of hepatocellular carcinoma incidence using a fibrosis-4-based prediction model in patients with chronic hepatitis C receiving antiviral therapy: a nationwide real-world Taiwanese cohort studyHung-Wei Wang, Pei-Chein Tsai, Chi-Yi Chen, et al.
Scientific Reports|March 28, 2020
Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritisWei-Fan Hsu, Chi-Yi Chen, Kuo-Chih Tseng, et al.
Journal of Gastroenterology and Hepatology|May 8, 2021
Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort)Wei-Fan Hsu, Pei-Chein Tsai, Chi-Yi Chen, et al.
Journal of Hepatology|October 8, 2022
Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in TaiwanPei-Chien Tsai, Hsing-Tao Kuo, Chao-Hung Hung, et al.
Journal of Gastroenterology and Hepatology|February 24, 2021
Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in TaiwanMeng-Hsuan Hsieh, Ming-Jong Bair, Pei-Chien Tsai, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
European Journal of Cancer (Oxford, England : 1990)|November 22, 2025
Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort studyTeng-Yu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|February 7, 2025
High-normal and abnormal alanine transaminase levels linked to increased risk of hepatoma following treatment for chronic hepatitis CYen-Chun Chen, Pei-Chien Tsai, Chung-Feng Huang, et al.
Clinical and Molecular Hepatology|February 5, 2025
Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort studyShou-Wu Lee, Sheng-Shun Yang, Pei-Chien Tsai, et al.
The American Journal of Gastroenterology|March 30, 2020
Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)Chung-Feng Huang, Hsueh-Chou Lai, Chi-Yi Chen, et al.
Hepatology International|August 8, 2021
Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)Ming-Lun Yeh, Chao-Hung Hung, Kuo-Chih Tseng, et al.
American Journal of Cancer Research|August 15, 2022
Risk stratification of hepatocellular carcinoma incidence using a fibrosis-4-based prediction model in patients with chronic hepatitis C receiving antiviral therapy: a nationwide real-world Taiwanese cohort studyHung-Wei Wang, Pei-Chein Tsai, Chi-Yi Chen, et al.
Scientific Reports|March 28, 2020
Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritisWei-Fan Hsu, Chi-Yi Chen, Kuo-Chih Tseng, et al.
Journal of Gastroenterology and Hepatology|May 8, 2021
Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort)Wei-Fan Hsu, Pei-Chein Tsai, Chi-Yi Chen, et al.
Journal of Hepatology|October 8, 2022
Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in TaiwanPei-Chien Tsai, Hsing-Tao Kuo, Chao-Hung Hung, et al.
Journal of Gastroenterology and Hepatology|February 24, 2021
Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in TaiwanMeng-Hsuan Hsieh, Ming-Jong Bair, Pei-Chien Tsai, et al.
Pageof 8